Gayoung Yu, MD
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1740712462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Corcept Therapeutics at 24.8% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NV, where the typical reported total is $4,060.
Across 112 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$949
- Dexcom, Inc.$367
- Novo Nordisk$346
- AbbVie$247
- Lilly USA, LLC$206
- Medtronic$175
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,823100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 11 | $949 |
| Dexcom, Inc. | 11 | $367 |
| Novo Nordisk | 12 | $346 |
| AbbVie | 12 | $247 |
| Lilly USA, LLC | 6 | $206 |
| Medtronic | 3 | $175 |
| Sanofi-aventis U.S. LLC | 3 | $175 |
| Amgen | 9 | $166 |
| BETA Bionics, Inc. | 4 | $160 |
| Insulet Corporation | 3 | $154 |
| Tandem Diabetes Care, Inc. | 1 | $124 |
| Boehringer Ingelheim | 7 | $110 |
| Novartis | 3 | $76 |
| Radius Health, Inc. | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Lifescan, Inc. | 2 | $56 |
| Chiesi USA, Inc. | 2 | $54 |
| Kyowa Kirin, Inc. | 2 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Mannkind Corporation | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Abbott | 1 | $30 |
| AstraZeneca | 2 | $29 |
| Sequel Med Tech, LLC | 1 | $23 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$478
- iLet Bionic Pancreas$330
- DEXCOM G6 TRANSMITTER$227
- MINIMED 780G$140
- Omnipod$134
- t:slim X2 Insulin Pump with Control-IQ$124
- MOUNJARO$120
- TZIELD$115
How this compares
$3,823 in reported general payments places this provider in the 45th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 361 | $389,070 |
| MounjaroTirzepatide | 151 | $192,513 |
| JardianceEmpagliflozin | 172 | $178,553 |
| TrulicityDulaglutide | 94 | $128,073 |
| Tresiba Flextouch U-100Insulin Degludec | 98 | $69,341 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $58,955 |
| ProliaDenosumab | 27 | $46,844 |
| FarxigaDapagliflozin Propanediol | 33 | $28,572 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $24,139 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $21,656 |
| Humalog Kwikpen U-100Insulin Lispro | 62 | $21,378 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 111 | $19,997 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $17,366 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 23 | $16,622 |
| TradjentaLinagliptin | 21 | $14,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $346 | $389,070361 claims |
| Lilly USA, LLCMounjaro, Trulicity | $206 | $320,586245 claims |
| Boehringer IngelheimJardiance, Tradjenta | $110 | $193,007193 claims |
| AmgenProlia | $166 | $46,84427 claims |
| AstraZenecaFarxiga | $29 | $28,57233 claims |
| AbbVieSynthroid | $247 | $2,41826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.